Your browser doesn't support javascript.
loading
Safety, tolerability, pharmacokinetics, and immunogenicity of a human monoclonal antibody targeting the G glycoprotein of henipaviruses in healthy adults: a first-in-human, randomised, controlled, phase 1 study.
Playford, Elliott Geoffrey; Munro, Trent; Mahler, Stephen M; Elliott, Suzanne; Gerometta, Michael; Hoger, Kym L; Jones, Martina L; Griffin, Paul; Lynch, Kathleen D; Carroll, Heidi; El Saadi, Debra; Gilmour, Margaret E; Hughes, Benjamin; Hughes, Karen; Huang, Edwin; de Bakker, Christopher; Klein, Reuben; Scher, Mark G; Smith, Ina L; Wang, Lin-Fa; Lambert, Stephen B; Dimitrov, Dimiter S; Gray, Peter P; Broder, Christopher C.
Afiliação
  • Playford EG; Infection Management Services, Princess Alexandra Hospital, Brisbane, QLD, Australia; School of Medicine, University of Queensland Brisbane, QLD, Australia. Electronic address: geoffrey.Playford@health.qld.gov.au.
  • Munro T; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.
  • Mahler SM; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.
  • Elliott S; Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia.
  • Gerometta M; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.
  • Hoger KL; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.
  • Jones ML; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.
  • Griffin P; Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia; Clinical Tropical Medicine Laboratory, QIMR Berghofer Medical Research Institute, Herston, QLD, Australia.
  • Lynch KD; Child Health Research Centre, Faculty of Medicine, University of Queensland Brisbane, QLD, Australia; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.
  • Carroll H; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.
  • El Saadi D; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.
  • Gilmour ME; Q-Pharm, Clive Berghofer Cancer Research Centre, Herston, QLD, Australia.
  • Hughes B; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.
  • Hughes K; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.
  • Huang E; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.
  • de Bakker C; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia.
  • Klein R; Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia.
  • Scher MG; Henry M Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA.
  • Smith IL; Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia.
  • Wang LF; Health and Biosecurity Business Unit, CSIRO Australian Animal Health Laboratory, Geelong, VIC, Australia; Programme in Emerging Infectious Diseases, Duke-National University Medical School, Singapore.
  • Lambert SB; Child Health Research Centre, Faculty of Medicine, University of Queensland Brisbane, QLD, Australia; Communicable Disease Branch, Prevention Division, Queensland Health, Brisbane, QLD, Australia.
  • Dimitrov DS; Center for Antibody Therapeutics, University of Pittsburgh Medical School, Pittsburgh, PA, USA.
  • Gray PP; Australian Institute for Bioengineering and Nanotechnology, University of Queensland Brisbane, QLD, Australia; ARC Training Centre for Biopharmaceutical Innovation, University of Queensland Brisbane, QLD, Australia.
  • Broder CC; Department of Microbiology and Immunology, Uniformed Services University, Bethesda, MD, USA.
Lancet Infect Dis ; 20(4): 445-454, 2020 04.
Article em En | MEDLINE | ID: mdl-32027842
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Segurança / Glicoproteínas / Henipavirus / Anticorpos Monoclonais Humanizados / Voluntários Saudáveis / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Adult / Female / Humans / Male País/Região como assunto: Oceania Idioma: En Revista: Lancet Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Segurança / Glicoproteínas / Henipavirus / Anticorpos Monoclonais Humanizados / Voluntários Saudáveis / Imunogenicidade da Vacina Tipo de estudo: Clinical_trials / Etiology_studies / Guideline Limite: Adult / Female / Humans / Male País/Região como assunto: Oceania Idioma: En Revista: Lancet Infect Dis Assunto da revista: DOENCAS TRANSMISSIVEIS Ano de publicação: 2020 Tipo de documento: Article